Literature DB >> 25250634

A structural and functional acromegaly classification.

Daniel Cuevas-Ramos1, John D Carmichael, Odelia Cooper, Vivien S Bonert, Arkadiusz Gertych, Adam N Mamelak, Shlomo Melmed.   

Abstract

CONTEXT: GH-secreting pituitary adenomas exhibit heterogeneous natural history ranging from small tumors to large aggressive adenomas.
OBJECTIVE: To rigorously classify an acromegaly patient cohort defined by clinical, radiological, histopathological, and outcome characteristics.
DESIGN: Cross-sectional study.
SETTING: Tertiary referral pituitary center. PATIENTS: Subjects were selected from a pituitary tumor research registry that includes 1178 patients with pituitary disease. Cluster analysis was performed on 338 acromegaly patients.
INTERVENTIONS: None. MAIN OUTCOME MEASURES: Biochemically active disease with elevated IGF-1 levels at follow-up.
RESULTS: Cluster analysis of all patients yielded 292 who were rigorously classified to three acromegaly types. Type 1 (50%) comprised older patients with the longest follow-up and most favorable outcomes, characterized by densely granulated, nonaggressive microadenomas and macroadenomas. Type 1 tumors extend to the sphenoid sinus more frequently than suprasellar extension (concave tumor image) and express abundant immunoreactive p21 and somatostatin receptor 2. Type 2 (19%) comprised noninvasive, densely or sparsely granulated macroadenomas, without significant extension (flat tumor image), with intermediate biochemical outcome. Type 3 (31%) was characterized by sparsely granulated aggressive macroadenomas and comprised patients with adverse therapeutic outcomes, despite receiving more treatments. These tumors extend to both the sphenoid sinus and suprasellar regions with commonly encountered optic chiasm compression ("peanut" magnetic resonance image), with low tumor p21 and somatostatin receptor 2 expression.
CONCLUSIONS: After validation, this classification may be useful to accurately identify acromegaly patients with distinctive patterns of disease aggressiveness and outcome, as well as to provide an accurate tool for selection criteria in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25250634      PMCID: PMC4283008          DOI: 10.1210/jc.2014-2468

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

1.  Atypical pituitary adenomas: incidence, clinical characteristics, and implications.

Authors:  Gabriel Zada; Whitney W Woodmansee; Shakti Ramkissoon; Jordan Amadio; Vania Nose; Edward R Laws
Journal:  J Neurosurg       Date:  2010-09-24       Impact factor: 5.115

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.

Authors:  I M Holdaway; M J Bolland; G D Gamble
Journal:  Eur J Endocrinol       Date:  2008-06-04       Impact factor: 6.664

Review 4.  Resistance to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Renata S Auriemma; Gaetano Lombardi; Rosario Pivonello
Journal:  Endocr Rev       Date:  2010-12-01       Impact factor: 19.871

Review 5.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

6.  Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.

Authors:  John A Jane; Robert M Starke; Mohamed A Elzoghby; Davis L Reames; Spencer C Payne; Michael O Thorner; John C Marshall; Edward R Laws; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06-29       Impact factor: 5.958

7.  p21(Cip1) restrains pituitary tumor growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kalman Kovacs; Anat Ben-Shlomo; Kolja Wawrowsky; Serguei Bannykh; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

Review 8.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed.

Authors:  Tirissa J Reid; Kalmon D Post; Jeffrey N Bruce; M Nabi Kanibir; Carlos M Reyes-Vidal; Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-16       Impact factor: 3.478

10.  Lineage-specific restraint of pituitary gonadotroph cell adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Cuiqi Zhou; Anat Ben-Shlomo; Kolja Wawrowsky; Yoel Toledano; Yunguang Tong; Kalman Kovacs; Bernd Scheithauer; Shlomo Melmed
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more
  33 in total

Review 1.  Endocrinology research-reflecting on the past decade and looking to the next.

Authors:  Kevan C Herold; Joseph A Majzoub; Shlomo Melmed; Merri Pendergrass; Martin Schlumberger
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

Review 2.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 5.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 6.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.

Authors:  Hussain Alquraini; Maria Del Pilar Schneider; Beloo Mirakhur; Ariel Barkan
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 8.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

Review 9.  New therapeutic agents for acromegaly.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2015-11-27       Impact factor: 43.330

10.  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Nan Deng; Evelyn Ding; Masaaki Yamamoto; Adam Mamelak; Vera Chesnokova; Artak Labadzhyan; Shlomo Melmed
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.